Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)

NCT: NCT07567027 · NOT_YET_RECRUITING

NCT IDNCT07567027
StatusNOT_YET_RECRUITING
Start Date2026-06-01
Completion2028-06-01

Brief Summary

The purpose of this study is to evaluate the feasibility, safety, and potential protective benefit of Barrigel, a hyaluronic acid-based rectal spacer, in patients undergoing prostate cryoablation for localized or recurrent prostate cancer. The primary aim is to assess Barrigel thermal stability during cryoablation.

Frequently Asked Questions

What is Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)?

Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR) is a clinical trial registered under NCT07567027. Current status: NOT_YET_RECRUITING.

What is the status of NCT07567027?

The current status of NCT07567027 (Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)) is: NOT_YET_RECRUITING.

When did Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR) start?

Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR) started on 2026-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑